Edwards Lifesciences Corp. announced on 19 May it received the CE mark for its PASCAL transcatheter tricuspid valve repair (TTVR) system for treating patients with tricuspid regurgitation, a disorder that causes blood to flow backward into the heart’s atrium when the right lower heart chamber contracts.
PASCAL is indicated in Europe for the percutaneous reconstruction of the tricuspid valve through
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?